All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 4, 2021
See today's BioWorld
Home
» Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma
To read the full story,
subscribe
or
sign in
.
Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma
Dec. 5, 2006
By
Karen Carey
No Comments
A Phase III failure of Nexavar in advanced melanoma thumped Onyx Pharmaceuticals Inc.'s stock by more than 30 percent Monday. (BioWorld Today)
BioWorld
